Prepare for a Payer Evidence Request

A payer evidence request lands in your inbox looking routine, a list of documents and a deadline. Underneath it sits a harder question. The committee wants to know if your drug earns a spot on their formulary, and every word you write back either helps them decide or gets read as a sales pitch. Handle it well and you look like a partner who understands their process. Handle it poorly and you look like someone trying to skip the line.

Why This Conversation Goes Wrong

Most market access managers stumble here for one reason, they treat the evidence request as a negotiation instead of an information exchange. The payer is not asking you to make a case. They are asking you to supply what their committee needs to run its own review. When you respond with enthusiasm about outcomes data or start hinting at favorable placement, you signal that you do not understand the difference between advocacy and evidence submission. Payer reviewers see this constantly and it costs you credibility before the committee even meets.

The other common failure is vagueness. You send a broad packet of studies without asking what format the committee actually wants, then discover after submission that half your materials do not meet their citation standard or fall outside the review scope. Now you are resubmitting under time pressure, which reads as disorganized to a group that already has hundreds of packets to get through. The fix for both problems starts before you ever reply to the request.

How To Prepare

Read the request twice before you respond. Note exactly what materials the committee has asked for, what format they specify, and what deadline applies. If any of that is unclear, your first move is to ask, not to assume. Find out how the committee wants sources labeled, whether they expect full methodology detail or a summary, and who on their side owns questions after the meeting. These details vary by payer, and guessing wrong wastes a review cycle.

Confirm internally which materials are approved for external use before you send anything. If the committee asks a question that drifts into scientific exchange, that is a signal to loop in medical affairs rather than answer it yourself. Market access managers who try to field clinical questions alone often say more than they should, and once a claim is out it is hard to walk back. Build your response around a simple structure, what you are sending, why it matches their stated criteria, and who to contact with follow up questions. If your team has not mapped out who among the payer's staff actually influences this decision, read Build the Right Stakeholder Plan for a Payer Review before your next submission. Knowing who reads the packet changes how you frame it.

What To Say

Picture a pharmacy director at a health plan who asks you directly, "If we move forward with your submission, can you confirm this gets you preferred placement?"

You answer, "Placement comes out of your committee's review process, so I cannot commit to an outcome. What I can do is make sure you have the evidence your reviewers need and get you fast answers on anything that comes up. Can you tell me what would make this packet easiest for your committee to work with?"

The director says, "Citations need to follow our standard format, and we need everything in by the fifteenth for the next cycle."

You reply, "Understood. I will confirm our citation format matches what you use and get the full packet to you by the fifteenth. If your reviewers have questions on the clinical data after that, I will bring in our medical affairs contact directly so you get a precise answer."

Notice what did not happen in that exchange. You did not promise an outcome, and you did not let the question sit unanswered either. You redirected toward the thing you actually control, which is the quality and timeliness of what you submit. You also asked a direct question back, which is often the fastest way to learn what actually matters to a committee instead of guessing at it.

Mistakes To Avoid

Do not answer a placement question with a maybe or a soft version of a promise. Saying something like "I think this data makes a strong case for preferred status" is functionally the same as guaranteeing an outcome, and payer reviewers will hold you to it later. Say plainly that placement is their decision, then move the conversation toward what you can deliver.

Do not send materials that have not been cleared for external use just because they seem relevant. If a study has not gone through your internal approval process, it does not go in the packet, no exceptions, even if you think it strengthens your case.

Do not treat a scientific question as something you can answer on the spot. If a reviewer asks about mechanism of action or safety data outside the approved messaging, tell them you will connect a medical affairs colleague rather than improvising an answer. Improvised answers create inconsistency between what you said and what the official record shows, and that inconsistency gets noticed.

Do not let the request sit without a written follow up. A phone call or a verbal agreement does not give the committee anything they can act on. Put the requested materials, the submission date, and your contact for questions into a short written summary every time.

How To Practice And Score It

Have a manager or colleague play the payer reviewer and push hard for a commitment on formulary status. The person playing the reviewer should ask the placement question at least twice, once directly and once phrased as a hypothetical, to see if the market access manager holds the same line both times.

Score the response against three things. Did the manager avoid promising or implying a placement outcome. Did the manager ask a specific question to learn the committee's actual requirements rather than guessing. Did the manager name a concrete deliverable, meaning a specific set of materials and a specific date, rather than a vague assurance to follow up soon.

Then check the written follow up against the same standard the call was scored on. It should list the exact evidence requested, name who owns the committee's process on their end, and state the date by which questions or additional materials are due. If any of those three pieces are missing, the manager has not finished the job even if the call itself went well. Practicing this scenario repeatedly, through Pharmaceuticals practice conversations or with a colleague standing in as the payer, builds the reflex to redirect toward process instead of promises. If your next meeting also involves a PBM raising scientific questions about the drug itself, Build a PBM Meeting Agenda for Scientific Questions covers how to structure that separately from the evidence packet.

The Close

A payer evidence request is not a sales conversation, it is a process you need to respect and support with clean information. Get the requirements right, keep your materials within approved bounds, and put every commitment in writing. Do that consistently and the committee will trust your submissions long before they trust your product claims, and DealSpeak gives you a way to rehearse that discipline before the real request lands in your inbox.